Round robin test on quantification of amyloid-β 1-42 in cerebrospinal fluid by mass spectrometry

Alzheimers Dement. 2016 Jan;12(1):55-9. doi: 10.1016/j.jalz.2015.06.1890. Epub 2015 Jul 21.

Abstract

Introduction: Cerebrospinal fluid (CSF) amyloid-β 1-42 (Aβ42) is an important biomarker for Alzheimer's disease, both in diagnostics and to monitor disease-modifying therapies. However, there is a great need for standardization of methods used for quantification. To overcome problems associated with immunoassays, liquid chromatography-tandem mass spectrometry (LC-MS/MS) has emerged as a critical orthogonal alternative.

Methods: We compared results for CSF Aβ42 quantification in a round robin study performed in four laboratories using similar sample preparation methods and LC-MS instrumentation.

Results: The LC-MS results showed excellent correlation between laboratories (r(2) >0.98), high analytical precision, and good correlation with enzyme-linked immunosorbent assay (r(2) >0.85). The use of a common reference sample further decreased interlaboratory variation.

Discussion: Our results indicate that LC-MS is suitable for absolute quantification of Aβ42 in CSF and highlight the importance of developing a certified reference material.

Keywords: Amyloid beta; Cerebrospinal fluid; Interlaboratory study; Mass spectrometry.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Alzheimer Disease / cerebrospinal fluid
  • Amyloid beta-Peptides / cerebrospinal fluid*
  • Biomarkers / cerebrospinal fluid*
  • Calibration
  • Chromatography, Liquid / methods*
  • Enzyme-Linked Immunosorbent Assay / standards
  • Humans
  • Peptide Fragments / cerebrospinal fluid*
  • Reference Standards
  • Tandem Mass Spectrometry / methods*

Substances

  • Amyloid beta-Peptides
  • Biomarkers
  • Peptide Fragments
  • amyloid beta-protein (1-42)